Skip to main content

Table 2 Maternal and neonatal/perinatal outcomes in women with gestational diabetes mellitus (GDM) treated vs. not treated with myoinositol

From: Myoinositol supplementation in the treatment of gestational diabetes mellitus: effects on glycaemic control and maternal-foetal outcomes

  Patients treated with myoinositol
(n= 150)
Patients not treated with myoinositol
(n= 180)
P
  Subjects (%) Subjects (%)  
Obstetrical outcomes
 Gestational hypertension 9 (6%) 7 (3.8%) 0.150
 Preeclampsia 9 (6%) 5 (2.7%) 0.137
 Preterm delivery 8 (5.3%) 16 (8.8%) 0.055
 Caesarean rate 40 (26.6%) 36 (20%) 0.156
 Recurrent glycosuria 13 (8.6%) 16 (8.8%) 0.948
 Recurrent ketonuria 35 (23.3%) 33 (18.3%) 0.263
  Mean ± SD Mean ± SD  
Neonatal and perinatal outcomes
 Birth weight (g) 3241 ± 443 3361 ± 406 0.043
 Birth weight percentiles 72.6 ± 12.6 75.4 ± 13.7 0.056
 Birth length (cm) 49.6 ± 1.83 49.3 ± 1.87 0.426
 Birth length percentiles 60 ± 16.6 59.2 ± 18.6 0.703
 APGAR score 8.89 ± 0.91 9.13 ± 0.77 0.070
  Subjects (%) Subjects (%)  
Large for gestational age (LGA) 13 (8.8%) 13 (7.2%) 0.592
Small for gestational age (SGA) 12 (8%) 25 (13.8%) 0.096
Hypoglycaemia 11 (7.3%) 36 (20%) 0.001
NICU stay 8 (5.3%) 5 (2.7%) 0.224
Hyperbilirubinemia 18 (12%) 12 (6.6%) 0.089
Respiratory distress syndrome 4 (2.6%) 3 (1.6%) 0.524
  1. NICU neonatal intensive care unit